Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome

被引:76
作者
Earley, CJ [1 ]
Heckler, D [1 ]
Allen, RP [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA
关键词
restless legs syndrome; iron; ferritin; treatment; ferrlecit; intravenous;
D O I
10.1016/j.sleep.2005.01.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: To evaluate in RLS patients the efficacy and safety of repeated infusions of iron in order to maintain symptomatic improvements achieved with a prior single 1000 mg infusion of iron. Patients and methods: Subjects who had demonstrated initial improvement in RLS symptoms after a single 1000 mg infusion of iron were evaluated monthly for serum ferritin and RLS severity. If symptoms returned at any time in the 2-year period after initial iron treatment, supplemental 450 mg iron gluconate infusions could be given, provided the ferritin was < 300 mcg/l. The primary outcome measures were side effect profile, duration (weeks) of sustained improvement, and rate of change of serum ferritin. Results: Ten subjects received the initial single 1000 mg dose of iron dextran, but only five subjects were eligible to receive supplemental iron infusions. RLS symptoms returned on average 6 months after the initial 1000 mg infusion. Because of noncompliance with monthly visits one subject was dropped after receiving three supplemental iron infusions. Because of a ferritin > 300 mcg/l, a second subject was dropped after having received one supplemental treatment. Three subjects completed the 2-year period of the study, having received between two and four courses of supplemental iron. After the initial 1000 mg iron infusion, the ferritin declined on average 6.6 mcg/l/week, which was substantially higher than the predicted value of < 1 mcg/l per week. The rate of ferritin decline decreased toward normal with repeated IV iron treatments: the average rate of decline in ferritin for the last treatment course was 2.3 mcg/l/wk. The slower the rate of ferritin decline the more prolonged the symptom improvements. Conclusions: Supplemental iron treatments can sustain previously achieved improvements with a single IV iron treatment, but achieving high ferritin levels was not in themselves a guarantee of sustained improvements. The most notable finding was the post-infusion changes in serum ferritin and its implication for altered iron excretion. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:301 / 305
页数:5
相关论文
共 13 条
[1]   MRI measurement of brain iron in patients with restless legs syndrome [J].
Allen, RP ;
Barker, PB ;
Wehrl, F ;
Song, HK ;
Earley, CJ .
NEUROLOGY, 2001, 56 (02) :263-265
[2]   Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome [J].
Connor, JR ;
Boyer, PJ ;
Menzies, SL ;
Dellinger, B ;
Allen, RP ;
Ondo, WG ;
Earley, CJ .
NEUROLOGY, 2003, 61 (03) :304-309
[3]   Iron absorption and transport [J].
Conrad, ME ;
Umbreit, JN ;
Moore, EG .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1999, 318 (04) :213-229
[4]   Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome [J].
Earley, CJ ;
Connor, JR ;
Beard, JL ;
Malecki, EA ;
Epstein, DK ;
Allen, RP .
NEUROLOGY, 2000, 54 (08) :1698-1700
[5]   The treatment of restless legs syndrome with intravenous iron dextran [J].
Earley, CJ ;
Heckler, D ;
Allen, RP .
SLEEP MEDICINE, 2004, 5 (03) :231-235
[6]   Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome [J].
Earley, CJ ;
Yaffee, JB ;
Allen, RP .
NEUROLOGY, 1998, 51 (06) :1599-1602
[7]  
Earley CJ, 2000, J NEUROSCI RES, V62, P623, DOI 10.1002/1097-4547(20001201)62:5<623::AID-JNR1>3.0.CO
[8]  
2-H
[9]   Hepcidin in iron metabolism [J].
Ganz, T .
CURRENT OPINION IN HEMATOLOGY, 2004, 11 (04) :251-254
[10]   BODY IRON EXCRETION IN MAN - A COLLABORATIVE STUDY [J].
GREEN, R ;
CHARLTON, R ;
SEFTEL, H ;
BOTHWELL, T ;
MAYET, F ;
ADAMS, B ;
FINCH, C ;
LAYRISSE, M .
AMERICAN JOURNAL OF MEDICINE, 1968, 45 (03) :336-&